BioSpace News Archive

Helius Medical Technologies, Inc, announced today the closing of an underwritten public offering of units for gross proceeds of approximately $11.0 million, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Helius.

Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be presenting at the following upcoming virtual investor conference

Genetic Disease Investigators, LLC, a company engaged in the research of dysautonomia, Postural Orthostatic Tachycardia Syndrome (POTS), Chronic Fatigue Syndrome, and similar “invisible” illnesses, announced today that the Canadian Intellectual Property Office issued Canadian Patent No. 2940871 (“Methods and Compositions for Correction of Organ Dysfunction”).

Cagent Vascular, a developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its PRELUDE-BTK Study at this year’s LINC Symposium on January 29th.

Case Western Reserve University and University Hospitals have extended their affiliation through 2031 in an amendment that expands opportunities for collaboration between the two organizations — and with others across Northeast Ohio.

ILIAS Biologics, Inc. announced that its latest research in collaboration with researchers at The University of Texas Medical Brand at Galveston (UTMB) is published in the journal Science Advances(Link: https://advances.sciencemag.org/content/7/4/eabd3865).

SGD Pharma, a leading supplier of glass primary packaging in the pharmaceutical industry, has been awarded a ‘platinum’ rating by EcoVadis, positioning it in the top 1% of all companies rated worldwide.

Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today the closing of a private placement financing, raising gross proceeds of $4.4 million

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the appointment of Joseph Soffer, M.D., F.A.C.C., as Executive Director of Clinical Development, effective immediately

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced early positive data from its ongoing U.S. Phase I controlled, observer-blinded clinical trial of inhaled Ampion versus standard of care for patients with COVID-19 respiratory distress (AP-014).